Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304914 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Ulrich Jarry und 14 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Afatinib, Bevacizumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Région Bretagne.
Abstract (Originalsprache)
Lung cancer is one of the most common and deadliest cancers. Preclinical models are essential to study new therapies and combinations taking tumor genetics into account. We have established cell lines expressing the luciferase gene from lines with varied genetic backgrounds, commonly encountered in patients with pulmonary adenocarcinoma. We have characterized these lines by testing their response to multiple drugs. Thus, we have developed orthotopic preclinical mouse models of NSCLC with very high engraftment efficiency. These models allow the easy monitoring of tumor growth, particularly in response to treatment, and of tumor cells dissemination in the body. We show that concomitant treatment with osimertinib (3rd generation tyrosine kinase inhibitor targeting mutated EGFR) and bevacizumab (anti-angiogenic targeting VEGF) can have a beneficial therapeutic effect on EGFR-mutated tumors. We also show that the addition of afatinib to osimertinib-treated tumors in escape leads to tumor growth inhibition. No such effect is observed with selumetinib or simvastatin. These preclinical mouse models therefore make it possible to test innovative therapeutic combinations and are also a tool of choice for studying resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.
- Biotrial Pharmacology, Unité de Pharmacologie Préclinique, Rennes, France.
- Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.
- Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.
ORCID-Profile: Ulrich Jarry
Förderung
- Agence Nationale de la Recherche
- Région Bretagne
Zitieren
APA
Jarry, U., Bostoen, M., Archambeau, J., Pineau, R., Chaillot, L., Jouan, F., Solhi, H., Ferrari, H., Le Guevel, R., Mennessier, V., Lena, H., Corre, R., Ricordel, C., Guillaudeux, T., & Pedeux, R. (2024). Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0304914
Vancouver
Jarry U, Bostoen M, Archambeau J, Pineau R, Chaillot L, Jouan F, et al. Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0304914
BibTeX
@article{Jarry2024,
author = {Jarry, Ulrich and Bostoen, Megane and Archambeau, Jérome and Pineau, Raphaël and Chaillot, Laura and Jouan, Florence and Solhi, Hélène and Ferrari, Hugo and Le Guevel, Rémy and Mennessier, Valentine and Lena, Hervé and Corre, Romain and Ricordel, Charles and Guillaudeux, Thierry and Pedeux, Rémy},
title = {Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304914}
}
EUVIMED